No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Express News | Esperion Strengthens Balance Sheet With Closing of Significant Refinancing Transactions
Goldman Sachs Upgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Raises Target Price to $4
Cantor Fitzgerald Initiates Esperion Therapeutics(ESPR.US) With Buy Rating, Announces Target Price $8
Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target
12 Health Care Stocks Moving In Friday's Pre-Market Session
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $6